SD-101, Nivolumab, and Radiation Therapy in Treating Patients With Chemotherapy-Refractory Metastatic Pancreatic Cancer
Conditions: Metastatic Pancreatic Adenocarcinoma; Refractory Pancreatic Adenocarcinoma; Stage IV Pancreatic Cancer AJCC v8 Interventions: Biological: Nivolumab; Radiation: Radiation Therapy; Drug: TLR9 Agonist SD-101 Sponsors: University of California, Davis; National Cancer Institute (NCI); Bristol-Myers Squibb; Dynavax Technologies Corporation Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Adenocarcinoma | Cancer | Cancer & Oncology | Chemotherapy | Pancreas | Pancreatic Cancer | Radiation Therapy | Research